Abstract: On the basis of the experimental results it has emerged that relaxin has a pro-differentiating effect on stem cells. It is therefore suggested the use of this hormone as principal component of a drug for the treatment of all those situations that find or will find benefit from the use of stem cells for the reconstruction of tissues damaged by traumatic events or by ischemic-inflammatory-degenerative diseases. It is also suggested the use of relaxin for the treatment of syndromes deriving from the missing activation of stem cells during fetal development (at subsequent somatic-functional maturation), such as for example hypogonotropic hypogonadism with anosmia (Kallman's syndrome).

Abstract: Methods of using relaxin (RLX), a peptide hormone of the insulin family, which has been found to produce effects on the walls of blood vessels, on blood clotting and on blood lipids and electrolytes, per se, and through the stimulation of the synthesis and release of the two powerful substances: nitric oxide (NO) and atrial natriuretic peptide (ANP), are contemplated whereby RLX is administered to a patient for increasing blood flow, producing dilation of the arteries, influencing blood clotting and fibrinolysis, reducing blood lipids, inducing reduction of blood osmolarity and sodium concentration, and through NO for inhibiting release of histamine from mast cells. RLX is accordingly used as a therapeutic agent in methods for treating arteriosclerosis and vascular diseases, ischemia and thrombosis, hypertension and pregnancy's gestosis, and other diseases, or allergic and inflammatory disorders as dysfunctions in fluid and electrolyte balance.

Abstract: Human Relaxin is recovered from human fetal membranes, and preferably from the chorion-decidua membranes.